Skip to main content

European Clinical Research Alliance on Infectious Diseases (ECRAID) - Business Plan

Periodic Reporting for period 1 - ECRAID-Plan (European Clinical Research Alliance on Infectious Diseases (ECRAID) - Business Plan)

Reporting period: 2019-01-01 to 2019-12-31

Infectious diseases pose a serious threat to global health. Emerging epidemics, pandemics and rising levels of antimicrobial resistance require a strong and coordinated response to protect citizens in Europe and beyond as indicated in the European One-Health Action Plan against AMR.
ECRAID aims to confront the ever present threat from ID head-on. The call text focuses on two major challenges in ID: emerging infectious diseases (EID) with epidemic or pandemic potential, caused by new or re-emerging pathogens, and antimicrobial resistance (AMR). These two challenges in ID will be the focus and mission of ECRAID. Our purpose is to reduce the impact of infectious diseases on individual and population health.
The overall goal of ECRAID-Plan is to develop the detailed business plan for ECRAID.
ECRAID-Plan was launched at a high-level kick off meeting in January 2019, Brussels. At the first consortium meeting in May the why, what, who of ECRAID-Plan was discussed. This resulted in a first draft of the business plan. Over the summer of 2019, three writing teams consisting of ECRAID-Plan’s partners continued to develop the service proposition of ECRAID, along with the operational aspects needed to offer these services. During the second consortium meeting in September the draft business plan was discussed with all partners, which led to a second version of the business plan. Furthermore, ECRAID’s service proposition was discussed with industry stakeholders during a workshop at the ESCMID conference in Boston. At the consortium meeting in December the focus was on fine-tuning the purpose, vision and mission and service offering of ECRAID. In the third version of the business plan these paragraphs are worked out in more detail.
At the end of the project, in December 2020, ECRAID-Plan has developed a detailed ECRAID business plan. This will serve three main purposes:
• Function as the central guiding document presenting the agreed strategy for the development of ECRAID;
• Serve as a means to build awareness of and support for ECRAID amongst stakeholders;
• Attract sufficient start-up funding/income to commence operations in ECRAID.

Once ECRAID is fully operational the following results are expected to be achieved:
1. Strengthening the operational capacity and the required infrastructures for clinical research.
2. Reducing the cost and time of clinical trials for diagnosis, prevention and treatment of infections and attracting industry back to invest in the development of anti-infectives.
3. Increasing information exchange between sectors and scientific disciplines.
4. Ensuring global collaboration between networks in Europe and other countries/regions to optimise a coordinated response to infectious diseases.
5. Maintaining Europe's leading role in combating AMR and controlling infectious diseases.